The American Medical Association (AMA) wants medical schools and residency programs to start training medical students and residents in healthcare economics.
The American Medical Association (AMA) wants medical schools and residency programs to start training medical students and residents in healthcare economics.
According to a new policy published this week, the AMA wants programs to incorporate education on the organization of healthcare delivery, modes of practice, practice settings, cost-effective use of diagnostic and treatment services, practice management, risk management, and quality assurance. These programs should also include content related to the environment and economics of medical practice in fee-for-service, managed-care, and other financing systems.
The AMA said the policy builds on its Health System Science curriculum, which launched in 2016 through its Accelerating Change in Medical Education Consortium; the AMA said knowledge about health systems is now considered the third leg of medical education that should be integrated with basic and clinical sciences education.
The move comes as patients are struggling with the costs of healthcare and specialty drugs for complex chronic diseases, rare diseases, and cancer. At the same time, physicians have seen a wave of change, as standalone clinician offices become increasingly rare, health systems combine, physician practices consolidate, and vertical integration of payers with data warehouses or retail pharmacies has become more common.
At the same time, CMS is launching new payment models and trying to incentivize physician behavior with 2-sided alternative payment reform.
“While many medical schools and residency programs currently provide students and residents with training in healthcare financing, it has become clear that future physicians require further instruction to ensure they are well-prepared to deliver care to patients in modern health systems,” said Barbara L. McAneny, MD, AMA’s immediate past president.
“Medical students and residents with a deeper understanding of cost, financing, and medical economics, will be better equipped to provide more cost-effective care that will have a positive impact for patients and the healthcare system as a whole. We will continue working to ensure future physicians are ready on day one to meet the needs of patients in the modern healthcare environment.”
The AMA includes a module on how payment models affect patient care and costs in its Graduate Medical Education Competency Education Program. The organization also said it recently published its Health System Science Review book, which includes information about value-based care and healthcare policy and economics.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.